Incyte Past Earnings Performance
Past criteria checks 5/6
Incyte has been growing earnings at an average annual rate of 25.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 13.7% per year. Incyte's return on equity is 11.5%, and it has net margins of 16.2%.
Key information
25.4%
Earnings growth rate
24.7%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 13.7% |
Return on equity | 11.5% |
Net Margin | 16.2% |
Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3,696 | 598 | 1,159 | 0 |
30 Sep 23 | 3,609 | 425 | 1,138 | 0 |
30 Jun 23 | 3,513 | 366 | 1,136 | 0 |
31 Mar 23 | 3,470 | 324 | 1,106 | 0 |
31 Dec 22 | 3,395 | 341 | 999 | 0 |
30 Sep 22 | 3,331 | 876 | 954 | 0 |
30 Jun 22 | 3,320 | 945 | 879 | 0 |
31 Mar 22 | 3,115 | 933 | 796 | 0 |
31 Dec 21 | 2,986 | 949 | 741 | 0 |
30 Sep 21 | 2,913 | 535 | 682 | 0 |
30 Jun 21 | 2,721 | 338 | 612 | 0 |
31 Mar 21 | 2,703 | 478 | 561 | 0 |
31 Dec 20 | 2,667 | -296 | 518 | 0 |
30 Sep 20 | 2,457 | -335 | 487 | 0 |
30 Jun 20 | 2,388 | -191 | 469 | 0 |
31 Mar 20 | 2,229 | -376 | 457 | 0 |
31 Dec 19 | 2,159 | 447 | 469 | 0 |
30 Sep 19 | 2,108 | 405 | 441 | 0 |
30 Jun 19 | 2,006 | 306 | 435 | 0 |
31 Mar 19 | 1,997 | 253 | 437 | 0 |
31 Dec 18 | 1,882 | 109 | 435 | 0 |
30 Sep 18 | 1,798 | -109 | 424 | 0 |
30 Jun 18 | 1,729 | -102 | 419 | 0 |
31 Mar 18 | 1,534 | -167 | 401 | 0 |
31 Dec 17 | 1,536 | -313 | 367 | 0 |
30 Sep 17 | 1,419 | -155 | 363 | 0 |
30 Jun 17 | 1,306 | -154 | 348 | 0 |
31 Mar 17 | 1,226 | -107 | 324 | 0 |
31 Dec 16 | 1,106 | 104 | 302 | 0 |
30 Sep 16 | 1,023 | 151 | 260 | 0 |
30 Jun 16 | 941 | 74 | 231 | 0 |
31 Mar 16 | 858 | 49 | 216 | 0 |
31 Dec 15 | 754 | 7 | 197 | 0 |
30 Sep 15 | 634 | -86 | 193 | 0 |
30 Jun 15 | 644 | 13 | 184 | 0 |
31 Mar 15 | 581 | -33 | 174 | 0 |
31 Dec 14 | 511 | -48 | 166 | 0 |
30 Sep 14 | 485 | -54 | 155 | 0 |
30 Jun 14 | 372 | -136 | 142 | 0 |
31 Mar 14 | 374 | -101 | 125 | 0 |
31 Dec 13 | 355 | -83 | 110 | 0 |
30 Sep 13 | 372 | -21 | 96 | 0 |
30 Jun 13 | 347 | -21 | 90 | 0 |
Quality Earnings: 0J9P has high quality earnings.
Growing Profit Margin: 0J9P's current net profit margins (16.2%) are higher than last year (10%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0J9P's earnings have grown significantly by 25.4% per year over the past 5 years.
Accelerating Growth: 0J9P's earnings growth over the past year (75.4%) exceeds its 5-year average (25.4% per year).
Earnings vs Industry: 0J9P earnings growth over the past year (75.4%) exceeded the Biotechs industry -11.5%.
Return on Equity
High ROE: 0J9P's Return on Equity (11.5%) is considered low.